Trials / Completed
CompletedNCT02450149
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study of sorafenib in patients with BRAF Mutation Refractory Solid Tumors. This study is a single-arm, pilot study of sorafenib in patients with Refractory Solid Tumors harboring BRAF Mutation Sorafenib 400 mg will be administered orally twice a day for 28 days. To investigate the efficacy of sorafenib in patients with Refractory Solid Tumors harboring BRAF Mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sorafenib |
Timeline
- Start date
- 2016-05-30
- Primary completion
- 2016-08-01
- Completion
- 2016-08-09
- First posted
- 2015-05-21
- Last updated
- 2017-03-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02450149. Inclusion in this directory is not an endorsement.